Stock Analysis, Dividends, Split History

FENCF / Fennec Pharmaceuticals, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price4.30
Volume8,700.00
Market Cap ($M)79.53
Enterprise Value ($M)55.77
Book Value ($M)24.86
Book Value / Share1.31
Price / Book3.28
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 18,464,706
Common Stock Shares Outstanding 18,411,000
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.26
Return on Assets (ROA)-1.77
Return on Equity (ROE)-1.97
Balance Sheet (mrq) ($M)
Assets25.70
Liabilities0.85
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Revenues0.00
Revenue From Grants0.00
Operating Income-6.95
Net Income-7.05
Earnings Per Share Diluted-0.47
Earnings Per Share Basic-0.47
Earnings Per Share Basic And Diluted-0.47
Cash Flow Statement (mra) ($M)
Cash From Operations-3.64
Cash from Investing0.00
Cash from Financing0.00
Identifiers and Descriptors
CUSIP31447P100
Central Index Key (CIK)1211583

Split History

Stock splits are used by Fennec Pharmaceuticals, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

REPH: Recro Pharma Analysis and Research Report

10h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

11h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

11h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

Related News Stories

Synergy Pharmaceuticals: Better Days Likely Ahead, But Better Opportunities Elsewhere

2018-06-13 seekingalpha
We look back at the flawed investment thesis we presented late last year and learn from our mistakes. (359-1)

Your Daily Pharma Scoop: Esperion Gains On Data, AnaptysBio's ANB020, Tesaro Reports Promising Data

2018-03-28 seekingalpha
Esperion Therapeutics (NASDAQ:ESPR) shares have moved up sharply after the company announced top-line results from a phase 2 study (1002-039) evaluating the LDL-C lowering efficacy and safety of bempedoic acid 180 mg added-on to stable background therapy of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in 58 patients with hypercholesterolemia. (158-3)

Fennec's stock soars further after PEDMARK receives 'breakthrough therapy' designation - MarketWatch

2018-03-27 marketwatch
Shares of Fennec Pharmaceuticals Inc. FENC, -0.37% were indicated up over 12% in premarket trade Tuesday, after the specialty pharmaceutical company said its PEDMARK to prevent cisplatin ototoxicity in pediatric patients with liver cancer was granted a "breakthrough therapy" designation by the Food and Drug Administration. Breakthrough therapy designation is given when there is preliminary clinical evidence that a treatment represents substantial improvement over available therapies, and includes fast-track program features. (2-0)

Top Analyst Upgrades and Downgrades: Apollo, ADM, Cigna, HubSpot, Intuit, Newmont, Nike, SAP, Time Warner and More

2018-03-12 247wallst
Stocks were up big on Friday after a solid jobs report and less wage inflation. The major stock market indexes were indicated to open marginally higher on Monday as well. The bull market is now more than nine years old, and the one trend that has prevailed for more than five years has been for investors to buy all the big pullbacks. Investors also still have to decide how they want to be positioned for the rest of 2018 and beyond. (187-4)

CUSIP: 31447P100